^
Association details:
| Biomarker: | PD-1 overexpression |
|---|---|
| Cancer: | Mesothelioma |
| Drug: | spartalizumab (PDR001) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1056P - Efficacy of spartalizumab across multiple cancer types in patients with PD1-high mRNA expressing tumors (SOLTI-1904 ACROPOLI)
Published date:
10/16/2023
Excerpt:
Regarding the updated efficacy results (data cutoff May2023), ORR was 17.2% (10/58) and CBR 29.3% (17/58). Clinical responses were observed in different cancer-types, including mesothelioma, sarcoma, carcinoma of primary unknown, cholangiocarcionoma, colorectal, ovarian, gastric and pancreatic cancers....Spartalizumab monotherapy demonstrated promising efficacy data and a favorable safety profile in heavily treated patients with immune-inflamed solid tumors expressing high levels of PD1 mRNA.
Trial ID:
